Warning Signs For Hospitals On Exchange Enrollment Falloff
For-profit hospital chains HCA and Tenet reported earnings for Q2 2026 and within the disclosures are tough news on Exchange revenue that could impact all hospitals.
HCA reported that its overall loss due to Exchange enrollment declines will go from an estimated $1 billion to a new projection of $1.2 billion in 2026. HCA says volume declines of 15% are in line with original guidance estimates, but its assumption that 80% to 85% of the patients who lose Exchange coverage would become uninsured has been off. The number is closer to 100%. HCA’s admission decline for Exchange enrollees has been between 25% and 28% for the first half of the year. The Exchange issues alone have caused a $400 million impact on adjusted EBITDA in Q2.
Similarly, Tenet Healthcare saw a 17% year-over-year decrease in Exchange-related revenue in Q2 and a 13.5% decrease in Exchange admissions.
Additional article: https://www.beckershospitalreview.com/finance/hcas-1-2b-aca-hit-raises-red-flag-for-nonprofit-health-systems
#hospitals #margins #exchanges
FDA Expands Peptide Compounding
The Food and Drug Administration’s (FDA) committee on compounded drugs voted in favor of adding new peptides to the list of substances compounding pharmacies can make, overruling the safety concerns expressed by agency scientists. Peptides are a favorite of Health and Human Services Secretary Robert F. Kennedy, Jr.
Meanwhile, a new study of another peptide, GLP-1s, finds benefits in lower work absence. The study found such medications resulted in employees taking 17% less long-term sick leave.
Additional article: https://thehill.com/policy/healthcare/5986855-glp-1-drugs-sick-leave-use-reduction-economic-study/
#peptides #fda #glp1s #weightlossdrugs
https://thehill.com/homenews/5987510-fda-committee-votes-peptides/
— Marc S. Ryan
